Short Interest in BioLineRx Ltd. (BLRX) Expands By 49.6%
BioLineRx Ltd. (NASDAQ:BLRX) was the target of a significant increase in short interest in the month of August. As of August 15th, there was short interest totalling 804,376 shares, an increase of 49.6% from the July 31st total of 537,795 shares. Based on an average daily trading volume, of 843,299 shares, the short-interest ratio is currently 1.0 days.
Several research firms recently issued reports on BLRX. Maxim Group set a $3.00 target price on shares of BioLineRx and gave the company a “buy” rating in a report on Tuesday, August 8th. Roth Capital set a $3.00 target price on shares of BioLineRx and gave the company a “buy” rating in a report on Wednesday, August 9th. HC Wainwright set a $4.00 target price on shares of BioLineRx and gave the company a “buy” rating in a report on Wednesday, August 9th. Zacks Investment Research lowered shares of BioLineRx from a “hold” rating to a “sell” rating in a report on Monday, August 14th. Finally, Oppenheimer Holdings, Inc. began coverage on shares of BioLineRx in a report on Friday, August 4th. They issued an “outperform” rating and a $3.00 target price on the stock. One analyst has rated the stock with a sell rating, one has given a hold rating and five have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus target price of $2.59.
Several hedge funds and other institutional investors have recently bought and sold shares of the company. Citadel Advisors LLC raised its stake in BioLineRx by 443.4% in the first quarter. Citadel Advisors LLC now owns 105,986 shares of the biotechnology company’s stock worth $102,000 after buying an additional 86,481 shares during the period. Renaissance Technologies LLC acquired a new stake in BioLineRx during the first quarter worth $126,000. Benchmark Capital Advisors raised its stake in BioLineRx by 227.3% in the first quarter. Benchmark Capital Advisors now owns 144,000 shares of the biotechnology company’s stock worth $138,000 after buying an additional 100,000 shares during the period. KCG Holdings Inc. raised its stake in BioLineRx by 715.9% in the first quarter. KCG Holdings Inc. now owns 175,156 shares of the biotechnology company’s stock worth $168,000 after buying an additional 153,687 shares during the period. Finally, Sabby Management LLC acquired a new stake in BioLineRx during the first quarter worth $3,018,000. Hedge funds and other institutional investors own 32.27% of the company’s stock.
Shares of BioLineRx (BLRX) opened at 1.03 on Thursday. BioLineRx has a 1-year low of $0.80 and a 1-year high of $1.42. The firm has a 50-day moving average of $1.02 and a 200 day moving average of $0.98. The company’s market capitalization is $98.49 million.
BioLineRx (NASDAQ:BLRX) last posted its quarterly earnings results on Tuesday, August 8th. The biotechnology company reported ($0.05) EPS for the quarter, hitting the Zacks’ consensus estimate of ($0.05). On average, equities research analysts expect that BioLineRx will post ($0.24) earnings per share for the current year.
WARNING: “Short Interest in BioLineRx Ltd. (BLRX) Expands By 49.6%” was first reported by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are viewing this news story on another site, it was illegally copied and reposted in violation of United States & international copyright legislation. The correct version of this news story can be viewed at https://theolympiareport.com/2017/08/31/short-interest-in-biolinerx-ltd-blrx-expands-by-49-6.html.
BioLine RX Ltd is an Israel-based company engaged in the development of therapeutics, from preclinical-stage development to advanced clinical trials, for a range of medical needs. Its clinical therapeutic candidates under development consist of BL-1020 that is in Phase II/III clinical trials to improve cognitive function in schizophrenia patients; BL-1040, which is under pivotal CE-Mark registration trial for the prevention of cardiac remodeling following an acute myocardial infarction; BL-5010, which has completed Phase I/II clinical trials for non-surgical removal of skin lesions; BL-1021 that has completed Phase Ia clinical trial for the treatment of neuropathic pain or pain that results from damage to nerve fibers, and BL-7040, a synthetic oligonucleotide, which is in Phase II clinical trial for the treatment of inflammatory bowel disease.
Receive News & Ratings for BioLineRx Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLineRx Ltd. and related companies with Analyst Ratings Network's FREE daily email newsletter.